Tranexamic Acid for Gastrointestinal Bleeding
Tranexamic acid (TXA) should not be used routinely to treat acute gastrointestinal (GI) bleeding outside randomized clinical trials. This recommendation is supported by the HALT-IT randomized trial, which found no reduction in death due to GI bleeding with high-dose TXA. [1], BSG/ACPGBI position statement
Evidence for TXA Effectiveness
HALT-IT (11,952 patients) compared a high-dose 24-hour IV TXA regimen with placebo in significant upper or lower GI bleeding and found no statistically significant reduction in death due to bleeding. [1]
A large individual-patient-data systematic review also concluded that mortality benefit seen in earlier smaller trials was not clearly supported by the higher-quality HALT-IT-level evidence. [2]
Some meta-analyses report reductions in rebleeding for TXA in acute GI bleeding, but these findings conflict with the most definitive large RCT evidence. [3]
Indications Where TXA Is Considered (Non–Acute Unselected GI Bleed)
TXA has a more established role in hereditary hemorrhagic telangiectasia–related gastrointestinal angiodysplasia (GIAD) when bleeding is difficult to control endoscopically. [4], [5]
This indication applies to specific bleeding syndromes rather than routine unselected “acute GI bleed” management. [4]
Practical Clinical Interpretation
TXA targets fibrinolysis and may reduce rebleeding in some settings. [3]
TXA has not demonstrated a consistent clinically meaningful mortality benefit in acute significant GI bleeding in the highest-quality evidence base. [1], [2]
Guideline-Consistent Position
The British Society of Gastroenterology position is that TXA should not be used for GI bleeding outside a randomized trial, based on HALT-IT results. BSG/ACPGBI position statement
Bottom-Line Answer to the Core Question
TXA can have hemostatic effects and may reduce rebleeding in some studies. [3]
TXA should not be relied upon to “stop a GI bleed” in routine emergency care because HALT-IT did not show benefit for death due to GI bleeding and major guidance statements advise against routine use outside trials. [1], BSG/ACPGBI position statement